Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 3,867 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 3,867 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the completion of the transaction, the insider owned 21,354 shares of the company’s stock, valued at $761,697.18. The trade was a 15.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The shares were sold at an average price of $54.28, for a total transaction of $62,801.96.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock opened at $36.53 on Friday. The firm has a market cap of $743.02 million, a P/E ratio of -4.58 and a beta of 1.31. The firm’s 50-day simple moving average is $48.85 and its 200-day simple moving average is $44.40. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $66.92.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.85) by $1.00. The firm had revenue of $11.79 million during the quarter, compared to analyst estimates of $10.20 million. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. On average, equities analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nektar Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its holdings in Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares during the last quarter. FNY Investment Advisers LLC boosted its stake in shares of Nektar Therapeutics by 70.6% in the 3rd quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 1,077 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of Nektar Therapeutics by 1,741.2% during the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 1,480 shares during the last quarter. Compass Wealth Management LLC acquired a new position in Nektar Therapeutics in the third quarter valued at approximately $88,000. Finally, Bayforest Capital Ltd acquired a new position in shares of Nektar Therapeutics in the 3rd quarter valued at $96,000. Institutional investors own 75.88% of the company’s stock.

Analysts Set New Price Targets

NKTR has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Monday, December 29th. Citigroup started coverage on Nektar Therapeutics in a research note on Wednesday, November 26th. They issued a “buy” rating and a $102.00 price objective on the stock. Finally, BTIG Research lifted their price target on Nektar Therapeutics from $100.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $111.83.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.